PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody

PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody

Tumor antigen-targeting monoclonal antibodies (TA-targeting mAbs) are used as therapeutics in many malignancies and their capacity to mobilize the host immunity puts them at the forefront of anti-cancer immunotherapies. Both innate and adaptive immune cells have been associated with the therapeutic...

Full description

Bibliographic Details
Main Authors: Laetitia They, Henri-Alexandre Michaud, Ondine Becquart, Virginie Lafont, Bernard Guillot, Florence Boissière-Michot, Marta Jarlier, Caroline Mollevi, Jean-François Eliaou, Nathalie Bonnefoy, Laurent Gros
Format: Article
Language:English
Published: Taylor & Francis Group 2017-10-01
Series:OncoImmunology
Subjects:
anti-tumor immunity
combined therapies
immunomodulation
long-lasting effects
tumor escape
tumor immune microenvironment
tumor-targeting monoclonal antibodies
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1353857

Internet

http://dx.doi.org/10.1080/2162402X.2017.1353857

Similar Items